Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs

被引：34

作者：

Anwar, Asif ^{[1
]}

Anwar, Imran John ^{[2
]}

Delafontaine, Patrice ^{[3
]}

机构：

[1] Tulane Univ, Sch Med, Inst Heart & Vasc, New Orleans, LA 70112 USA

[2] Tulane Univ, Sch Med, Dept Physiol, New Orleans, LA 70112 USA

[3] Univ Missouri, Sch Med, Dept Med, Columbia, MO 65212 USA

来源：

TRENDS IN CARDIOVASCULAR MEDICINE | 2015年 / 25卷 / 08期

关键词：

SELECTIVE CYCLOOXYGENASE-2 INHIBITORS; ACUTE MYOCARDIAL-INFARCTION; THERAPEUTIC ARTHRITIS RESEARCH; EVENT TRIAL TARGET; LOW-DOSE ASPIRIN; CYCLO-OXYGENASE-2; INHIBITORS; SUBCLINICAL ATHEROSCLEROSIS; GASTROINTESTINAL TOXICITY; RHEUMATOID-ARTHRITIS; COX-2;

D O I：

10.1016/j.tcm.2015.03.006

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most frequently used medications. NSAIDs profoundly modify prostaglandin homeostasis through inhibition of the enzyme, cyclooxygenase (COX), especially COX-2. COX-2 inhibition is associated with adverse cardiovascular outcomes as demonstrated by recent trials using this type of drug. This review explores the latest available data, including recent, randomized, clinical trials, controversies, and pathophysiology of the adverse effects of COX-inhibition. (C) 2015 Elsevier Inc. All rights reserved.

引用

页码：726 / 735

页数：10

共 62 条

[1]

Use of nonsteroidal Antiinflammatory drugs an update for clinicians - A scientific statement from the American Heart Association [J].

Antman, Elliott M. ;

Bennett, Joel S. ;

Daugherty, Alan ;

Furberg, Curt ;

Roberts, Harold ;

Taubert, Kathryn A. .

CIRCULATION, 2007, 115 (12) :1634-1642

[2]

Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71

[3]

Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial [J].

Baron, John A. ;

Sandler, Robert S. ;

Bresalier, Robert S. ;

Lanas, Angel ;

Morton, Dion G. ;

Riddell, Robert ;

Iverson, Erik R. ;

DeMets, David L. .

LANCET, 2008, 372 (9651) :1756-1764

[4]

Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Outcomes in Women Results From the Women's Health Initiative [J].

Bavry, Anthony A. ;

Thomas, Fridtjof ;

Allison, Matthew ;

Johnson, Karen C. ;

Howard, Barbara V. ;

Hlatky, Mark ;

Manson, JoAnn E. ;

Limacher, Marian C. .

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2014, 7 (04) :603-610

[5]

Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis [J].

Becker, Matthew C. ;

Wang, Thomas H. ;

Wisniewski, Lisa ;

Wolski, Kathy ;

Libby, Peter ;

Luescher, Thomas F. ;

Borer, Jeffrey S. ;

Mascette, Alice M. ;

Husni, M. Elaine ;

Solomon, Daniel H. ;

Graham, David Y. ;

Yeomans, Neville D. ;

Krum, Henry ;

Ruschitzka, Frank ;

Lincoff, A. Michael ;

Nissen, Steven E. .

AMERICAN HEART JOURNAL, 2009, 157 (04) :606-612

[6]

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials [J].

Bhala, N. ;

Emberson, J. ;

Merhi, A. ;

Abramson, S. ;

Arber, N. ;

Baron, J. A. ;

Bombardier, C. ;

Cannon, C. ;

Farkouh, M. E. ;

FitzGerald, G. A. ;

Goss, P. ;

Halls, H. ;

Hawk, E. ;

Hawkey, C. ;

Hennekens, C. ;

Hochberg, M. ;

Holland, L. E. ;

Kearney, P. M. ;

Laine, L. ;

Lanas, A. ;

Lance, P. ;

Laupacis, A. ;

Oates, J. ;

Patrono, C. ;

Schnitzer, T. J. ;

Solomon, S. ;

Tugwell, P. ;

Wilson, K. ;

Wittes, J. ;

Baigent, C. ;

Adelowo, O. ;

Aisen, P. ;

Al-Quorain, A. ;

Altman, R. ;

Bakris, G. ;

Baumgartner, H. ;

Bresee, C. ;

Carducci, M. ;

Chang, D-M. ;

Chou, C-T. ;

Clegg, D. ;

Cudkowicz, M. ;

Doody, L. ;

El Miedany, Y. ;

Falandry, C. ;

Farley, J. ;

Ford, L. ;

GarciLosa, M. ;

Gonzalez-Ortiz, M. ;

Haghighi, M. .

LANCET, 2013, 382 (9894) :769-779

[7]

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].

Bombardier, C ;

Laine, L ;

Reicin, A ;

Shapiro, D ;

Burgos-Vargas, R ;

Davis, B ;

Day, R ;

Ferraz, MB ;

Hawkey, CJ ;

Hochberg, MC ;

Kvien, TK ;

Schnitzer, TJ ;

Weaver, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528

[8]

Vane's discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology [J].

Botting, Regina M. .

PHARMACOLOGICAL REPORTS, 2010, 62 (03) :518-525

[9]

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].

Bresalier, RS ;

Sandler, RS ;

Quan, H ;

Bolognese, JA ;

Oxenius, B ;

Horgan, K ;

Lines, C ;

Riddell, R ;

Morton, D ;

Lanas, A ;

Konstam, MA ;

Baron, JA .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102

[10]

Brooks P., 1998, AM J MED, V104, p9S, DOI [DOI 10.1016/S0002-9343(97)00204-0, 10.1016/S0002-9343(97)00204-0]

← 1 2 3 4 5 6 7 →